Find a Trial

Trial Results


18 protocol(s) meet the specified criteria
20170543OPEN TO ACCRUAL
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100).
A151216OPEN TO ACCRUAL
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
CTO-BTCRC-LUN18-153OPEN TO ACCRUAL
A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153
CTO-BTCRC-LUN19-396OPEN TO ACCRUAL
A phase II study of adjuvant treatment with cisplatin-based chemotherapy plus concomitant atezolizumab in patients with stage I (tumors > 4cm), IIA, IIB, and select IIIA [T3N1-2, T4N0-2] resected non-small cell lung cancer (NSCLC) and the clearance of circulating tumor DNA (ctDNA)
CTO-IUSCC-0701OPEN TO ACCRUAL
Immunological Profile Changes In Patients with Advanced Non-Small Cell Lung Cancer Undergoing Treatment with Checkpoint Inhibitor Monotherapy
CTO-IUSCC-0722OPEN TO ACCRUAL
Circulating tumor DNA as a predictive biomarker to individualize therapy in patients with stage III non-small cell lung cancer
CTO-IUSCC-0723OPEN TO ACCRUAL
Evaluating the incidence and outcomes of patients with stage III non-small cell lung cancer (NSCLC) whose tumors harbor STK11 and/or Keap1 mutations treated with chemoradiation (CRT) followed by consolidation immunotherapy
CTO-IUSCCC-0770OPEN TO ACCRUAL
Serial Testing To Assess Cognitive Function In Patients With Cancer Being Treated With Immunotherapy
CTO-LUN18-335OPEN TO ACCRUAL
CTO-LUNGMAPOPEN TO ACCRUAL
A MASTER PROTOCOL TO EVALUATE BIOMARKER-DRIVEN THERAPIES AND IMMUNOTHERAPIES IN PREVIOUSLY-TREATED NON-SMALL CELL LUNG CANCER (Lung-MAP Screening Study)
E4512OPEN TO ACCRUAL
A Phase III Double Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
IUCRO-0031OPEN TO ACCRUAL
Molecular and Pathological Correlates of Treatment Outcome in Patients with Thymoma and Thymic Carcinoma
OTHN-IIR-IUSCC-0733OPEN TO ACCRUAL
Functional and Molecular Analysis of Muscle in Patients With and Without Head and Neck Cancer Cachexia
PSY-IIR-COVID-SURVEY-LCOPEN TO ACCRUAL
Long-term Adjustment to COVID-19 Among Lung Cancer Patients
PULM-IIR-DRCOPEN TO ACCRUAL
Analysis of DRC in lung disease
RAON-IIR-IUSCC-0711OPEN TO ACCRUAL
Combined Deep Inspiration Breath Hold (DIBH)-Expiration Planning Technique in Patients with Lung Tumors in Close Proximity to the Chest Wall
RAON-NRG-LU005OPEN TO ACCRUAL
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab.
S1701OPEN TO ACCRUAL
A RANDOMIZED PHASE II TRIAL OF CARBOPLATIN-PACLITAXEL WITH OR WITHOUT RAMUCIRUMAB IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED, RECURRENT, OR METASTATIC THYMIC CARCINOMA